By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TRANSGENE S.A. 

11 rue de MOLSHEIM, 67082
Strasbourg
Cedex      France
Phone: 011-33-3-88-27-91-21 Fax: 011-33-3-88-27-91-11


SEARCH JOBS


Industry
Biotechnology

Segment
Gene Therapy

Collaborations

Human Genome Sciences, Inc.  Gene Therapy Partnerships





Company News
TRANSGENE (ENX:TNG), UC Davis To Conduct Phase II Trial Of The Combination Of TG4010 With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC) 12/7/2016 11:27:42 AM
TRANSGENE (ENX:TNG) Presents Preclinical Results Of TG1050, An HBV-Targeted Immunotherapy, At American Association for Study of Liver Diseases 2016 Liver Meeting 11/14/2016 10:29:13 AM
TRANSGENE (ENX:TNG) Reports Third Quarter 2016 Financial Results 10/20/2016 10:56:26 AM
First Patient Randomized In Multiple Dose Cohort Of Phase 1/1b Trial With TRANSGENE (ENX:TNG)'s TG1050 In Chronic Hepatitis B Patients 10/17/2016 12:45:51 PM
TRANSGENE (ENX:TNG) Announces Collaboration With Merck KGaA (MKGAF.PK), Darmstadt, Germany, And Pfizer (PFE) To Evaluate The Combination Of TG4001 With Avelumab In HPV-Positive Head & Neck Cancer In A Phase I/II Study 10/11/2016 11:11:30 AM
TRANSGENE (ENX:TNG) Presents Data On Improved Cytotoxic Activity Of Oncolytic Viruses Expressing Intrabodies In Resistant Tumor Cell Lines 10/6/2016 11:49:41 AM
TRANSGENE (ENX:TNG) Provides An Update On Its Development Strategy And On Its First Half-Year 2016 Financials 9/6/2016 12:54:37 PM
TRANSGENE (ENX:TNG) Announces Participation At Upcoming Investor Events 9/1/2016 11:32:04 AM
TRANSGENE (ENX:TNG) To Continue Phase I/Ib Study With TG1050 In Chronic Hepatitis B Patients On The Recommendation Of The Trial’s Safety Review Committee 7/21/2016 12:51:38 PM
ASCO2016: TRANSGENE (ENX:TNG) Announces Poster Presentation At ASCO Annual Meeting On The Phase 3 PHOCUS Clinical Trial With Pexa-Vec Oncolytic Immunotherapy 5/31/2016 11:18:19 AM
12345678910...
//-->